Fibronectin type III domain-based fusion proteins
Provided herein are fusion proteins including at least one binding polypeptide and at least
one unstructured polypeptide. The fusion protein may further include at least one linker …
one unstructured polypeptide. The fusion protein may further include at least one linker …
Phase transition biopolymers and methods of use
US9771396B2 - Phase transition biopolymers and methods of use - Google Patents
US9771396B2 - Phase transition biopolymers and methods of use - Google Patents Phase …
US9771396B2 - Phase transition biopolymers and methods of use - Google Patents Phase …
Order and disorder as a design principle for stimuli-responsive biopolymer networks
A Chilkoti, S Roberts - US Patent 11,680,083, 2023 - Google Patents
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O [C@@ H] 1 [C@@
H](O)[C@ H](O)[C@@ H](CN) O [C@@ H] 1O [C@ H] 1 [C@ H](O)[C@@ H](O [C@@ H] 2 …
H](O)[C@ H](O)[C@@ H](CN) O [C@@ H] 1O [C@ H] 1 [C@ H](O)[C@@ H](O [C@@ H] 2 …
Polymer conjugates having reduced antigenicity and methods of using the same
A Chilkoti, Y Qi, MS Hershfield, NJ Ganson - US Patent 10,364,451, 2019 - Google Patents
Disclosed herein are compositions and methods for reducing the antigenicity of molecules.
The antigenicity of a molecule may be reduced or eliminated by conjugating at least one …
The antigenicity of a molecule may be reduced or eliminated by conjugating at least one …
Amphiphilic polynucleotides
A Chilkoti, S Zauscher, L Tang… - US Patent 11,965,164, 2024 - Google Patents
Compositions and methods disclosed herein can help provide improved delivery of non-
natural therapeutic nucleotides for the treatment of diseases such as cancer. An example …
natural therapeutic nucleotides for the treatment of diseases such as cancer. An example …
Genetically encoded polypeptide for affinity capture and purification of biologics
KM Luginbuhl, A Chilkoti - US Patent App. 18/346,456, 2024 - Google Patents
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O [C@@ H] 1 [C@@
H](O)[C@ H](O)[C@@ H](CN) O [C@@ H] 1O [C@ H] 1 [C@ H](O)[C@@ H](O [C@@ H] 2 …
H](O)[C@ H](O)[C@@ H](CN) O [C@@ H] 1O [C@ H] 1 [C@ H](O)[C@@ H](O [C@@ H] 2 …
Unstructured non-repetitive polypeptides having lcst behavior
A Chilkoti, T Nicholas, G Kelly - US Patent 12,084,480, 2024 - Google Patents
Described herein are unstructured polypeptides lacking any discernible repeat motif. Also
described herein are fusion proteins including at least one of the unstructured polypeptides …
described herein are fusion proteins including at least one of the unstructured polypeptides …
Dual agonist fusion proteins
A Chilkoti, C Gilroy - US Patent 11,649,275, 2023 - Google Patents
US11649275B2 - Dual agonist fusion proteins - Google Patents US11649275B2 - Dual
agonist fusion proteins - Google Patents Dual agonist fusion proteins Download PDF Info …
agonist fusion proteins - Google Patents Dual agonist fusion proteins Download PDF Info …
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
A61K31/704—Compounds having saccharide radicals attached to non-saccharide
compounds by glycosidic linkages attached to a carbocyclic compound, eg phloridzin …
compounds by glycosidic linkages attached to a carbocyclic compound, eg phloridzin …
Surfaces having reduced non-specific binding and antigenicity
A Hucknall, A Chilkoti, D Joh, NJ Ganson, Y Qi… - US Patent …, 2023 - Google Patents
Disclosed herein are compositions and methods for reducing the antigenicity of molecules.
The antigenicity of a molecule may be reduced or eliminated by conjugating at least one …
The antigenicity of a molecule may be reduced or eliminated by conjugating at least one …